Cargando…

淋巴肿瘤患者细菌性血流感染临床和细菌学分析

OBJECTIVE: To investigate the clinical status of lymphoid tissue neoplasms patients with bacteria bloodstream infections, bacteriology and drug susceptibility results, and provide the basis for rational clinical anti-infection option. METHODS: A retrospectively analysis of clinical data and bacteria...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342193/
https://www.ncbi.nlm.nih.gov/pubmed/29365397
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.12.007
_version_ 1783555399363854336
collection PubMed
description OBJECTIVE: To investigate the clinical status of lymphoid tissue neoplasms patients with bacteria bloodstream infections, bacteriology and drug susceptibility results, and provide the basis for rational clinical anti-infection option. METHODS: A retrospectively analysis of clinical data and bacterial susceptibility test results of patients with bacteria bloodstream infections from September 2010 to December 2014 was conducted. RESULTS: A total of 134 cases including 107 patients with bloodstream infections were enrolled. 84 cases were male, 50 cases were female, the median age was 31 (12–71) years old. 112 cases were agranulocytosis, and 106 cases were severe agranulocytosis (ANC<0.1×10(9)/L). 27 cases underwent hematopoietic stem cell transplantation, 100 cases received chemotherapy[33 cases with VD (I) CP±L (vincristine+daunorubicin/idarubicin + cyclophosphamide + prednison±asparaginasum) induction chemotherapy, 41 cases with intensive chemotherapy of Hyper-CVAD/MA or MA (mitoxantrone+cytarabine), 26 cases with other chemotherapy regimens], and 7 cases were infected without chemotherapy. 10 patients discharged from hospital owing to treatment abandoning, 120 cases were cured through anti-infective therapy, 2 patients died of bacteria bloodstream infections, 1 patient died of sudden cardiac, and 1 patient died of GVHD after allogenic hematopoietic stem cell transplantation. A total of 144 strains were isolated, including 108 strains (75.0%) of Gram-negative bacteria and 36 strains (25.0%) of Gram-positive cocci. The susceptibility of Gram-negative bacteria to the carbapenems was 98.00%, and the adjustment treatment rate of carbapenems was 3.0%. The susceptibility of Gram-negative bacteria to the other antibiotics was 60.30%, and the adjustment treatment rate was 90.5%. The susceptibility of Grampositive cocci to the carbapenems was 49.3%, and to glycopeptides and linezolid was 100.0%. Comparing all patients'empirical use of antimicrobial agents with the drugs susceptibility results of blood cultures, 80.1% of the patients'initial drug selection was sensitive. CONCLUSION: The lymphoid neoplasms patients experienced bacteria bloodstream infections most often after receiving the chemotherapy regimens of treating acute lymphoblastic leukemia. The majority type of bacteria was Gram-negative bacteria. Drug susceptibility test showed that susceptibility of Gram-negative bacteria to the carbapenems was the highest, and the treatment adjustment rate was obviously lower. The susceptibility of Gram-positive cocci to glycopeptides and linezolid was high, and which could be applied to the patients with Gram-positive cocci sepsis on basis of susceptibility results in general.
format Online
Article
Text
id pubmed-7342193
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73421932020-07-16 淋巴肿瘤患者细菌性血流感染临床和细菌学分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To investigate the clinical status of lymphoid tissue neoplasms patients with bacteria bloodstream infections, bacteriology and drug susceptibility results, and provide the basis for rational clinical anti-infection option. METHODS: A retrospectively analysis of clinical data and bacterial susceptibility test results of patients with bacteria bloodstream infections from September 2010 to December 2014 was conducted. RESULTS: A total of 134 cases including 107 patients with bloodstream infections were enrolled. 84 cases were male, 50 cases were female, the median age was 31 (12–71) years old. 112 cases were agranulocytosis, and 106 cases were severe agranulocytosis (ANC<0.1×10(9)/L). 27 cases underwent hematopoietic stem cell transplantation, 100 cases received chemotherapy[33 cases with VD (I) CP±L (vincristine+daunorubicin/idarubicin + cyclophosphamide + prednison±asparaginasum) induction chemotherapy, 41 cases with intensive chemotherapy of Hyper-CVAD/MA or MA (mitoxantrone+cytarabine), 26 cases with other chemotherapy regimens], and 7 cases were infected without chemotherapy. 10 patients discharged from hospital owing to treatment abandoning, 120 cases were cured through anti-infective therapy, 2 patients died of bacteria bloodstream infections, 1 patient died of sudden cardiac, and 1 patient died of GVHD after allogenic hematopoietic stem cell transplantation. A total of 144 strains were isolated, including 108 strains (75.0%) of Gram-negative bacteria and 36 strains (25.0%) of Gram-positive cocci. The susceptibility of Gram-negative bacteria to the carbapenems was 98.00%, and the adjustment treatment rate of carbapenems was 3.0%. The susceptibility of Gram-negative bacteria to the other antibiotics was 60.30%, and the adjustment treatment rate was 90.5%. The susceptibility of Grampositive cocci to the carbapenems was 49.3%, and to glycopeptides and linezolid was 100.0%. Comparing all patients'empirical use of antimicrobial agents with the drugs susceptibility results of blood cultures, 80.1% of the patients'initial drug selection was sensitive. CONCLUSION: The lymphoid neoplasms patients experienced bacteria bloodstream infections most often after receiving the chemotherapy regimens of treating acute lymphoblastic leukemia. The majority type of bacteria was Gram-negative bacteria. Drug susceptibility test showed that susceptibility of Gram-negative bacteria to the carbapenems was the highest, and the treatment adjustment rate was obviously lower. The susceptibility of Gram-positive cocci to glycopeptides and linezolid was high, and which could be applied to the patients with Gram-positive cocci sepsis on basis of susceptibility results in general. Editorial office of Chinese Journal of Hematology 2017-12 /pmc/articles/PMC7342193/ /pubmed/29365397 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.12.007 Text en 2017年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
淋巴肿瘤患者细菌性血流感染临床和细菌学分析
title 淋巴肿瘤患者细菌性血流感染临床和细菌学分析
title_full 淋巴肿瘤患者细菌性血流感染临床和细菌学分析
title_fullStr 淋巴肿瘤患者细菌性血流感染临床和细菌学分析
title_full_unstemmed 淋巴肿瘤患者细菌性血流感染临床和细菌学分析
title_short 淋巴肿瘤患者细菌性血流感染临床和细菌学分析
title_sort 淋巴肿瘤患者细菌性血流感染临床和细菌学分析
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342193/
https://www.ncbi.nlm.nih.gov/pubmed/29365397
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.12.007
work_keys_str_mv AT línbāzhǒngliúhuànzhěxìjūnxìngxuèliúgǎnrǎnlínchuánghéxìjūnxuéfēnxī
AT línbāzhǒngliúhuànzhěxìjūnxìngxuèliúgǎnrǎnlínchuánghéxìjūnxuéfēnxī
AT línbāzhǒngliúhuànzhěxìjūnxìngxuèliúgǎnrǎnlínchuánghéxìjūnxuéfēnxī
AT línbāzhǒngliúhuànzhěxìjūnxìngxuèliúgǎnrǎnlínchuánghéxìjūnxuéfēnxī
AT línbāzhǒngliúhuànzhěxìjūnxìngxuèliúgǎnrǎnlínchuánghéxìjūnxuéfēnxī
AT línbāzhǒngliúhuànzhěxìjūnxìngxuèliúgǎnrǎnlínchuánghéxìjūnxuéfēnxī
AT línbāzhǒngliúhuànzhěxìjūnxìngxuèliúgǎnrǎnlínchuánghéxìjūnxuéfēnxī
AT línbāzhǒngliúhuànzhěxìjūnxìngxuèliúgǎnrǎnlínchuánghéxìjūnxuéfēnxī
AT línbāzhǒngliúhuànzhěxìjūnxìngxuèliúgǎnrǎnlínchuánghéxìjūnxuéfēnxī
AT línbāzhǒngliúhuànzhěxìjūnxìngxuèliúgǎnrǎnlínchuánghéxìjūnxuéfēnxī
AT línbāzhǒngliúhuànzhěxìjūnxìngxuèliúgǎnrǎnlínchuánghéxìjūnxuéfēnxī
AT línbāzhǒngliúhuànzhěxìjūnxìngxuèliúgǎnrǎnlínchuánghéxìjūnxuéfēnxī